Clinical trials
HER2-positive Early Breast Cancer clinical trials
Below are recruiting her2-positive early breast cancer clinical trials, each written for real people, not researchers. We’re tracking 58 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07233499RecruitingPhase 2
Nebivolol for heart protection during breast cancer treatment
This trial tests if the drug nebivolol can protect the heart from damage caused by trastuzumab (Herceptin) in women with HER2-positive breast cancer. If effective, it may help prevent heart problems while still allowing cancer treatment.
CairoAges 18–65 - NCT07233928Recruiting
Breast cancer protein study in different subtypes
This trial takes a close look at the proteins inside breast cancer cells, using samples from people with different subtypes. It aims to better understand how each type behaves, which could help guide future treatments.
ToulouseAges 18 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Birmingham, AlabamaAges 18 years+ - NCT07455188Recruiting
Switching targeted therapies for advanced HER2-positive breast cancer
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
Zhejiang, HangzhouAges 18 years+ - NCT07459673RecruitingPhase 2
HER2-positive breast cancer trial using ctDNA to guide treatment
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
Basking Ridge, New JerseyAges 18 years+ - NCT07647263RecruitingPhase 2
New Drug Treatment Before Surgery for HER2-Positive Breast Cancer
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
Suzhou, JiangsuAges 18 years+ - NCT05914961Recruiting
Tracking inflammation response in triple-negative breast cancer
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
TübingenAges 18 years+ - NCT07066917Recruiting
Breast cancer treatment response study
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
AthensAges 18 years+ - NCT03561740RecruitingPhase 3
Capecitabine plus usual treatment for high-risk HER2 breast cancer
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Guangzhou, GuangdongAges 18–70 - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+
Hear when a new HER2-positive Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-positive early breast cancer?
- Yes. Clin2 currently lists 58 recruiting her2-positive early breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-positive early breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-positive early breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HER2-positive Breast Cancer
- HER2-positive Metastatic Breast Cancer
- HER2-positive Advanced Breast Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- HR+/HER2- Early Breast Cancer
- HR Positive/HER2 Low Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.